Meiji Holdings logo

Meiji Holdings

12
Innovation Areas

T-cell malignancy antigen selectivity: Meiji Holdings Last 5 Years research landscape

Therapeutic antibodies often fail to distinguish between malignant T-cells and healthy immune cells, causing systemic toxicity.